Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases.
The company believes that harnessing the body’s natural regulatory mechanisms through enhanced expression of microRNA-124 can transform the way inflammatory diseases are treated.
